Table 2.
Treatment Response | Ridaforolimus (N = 38) Number of Patients, n (%) |
---|---|
Complete Response | 0 (0) |
Partial Response | 0 (0) |
Stable Disease | 18 (47.4) |
Progressive Disease | 5 (13.2) |
Unable to Evaluate | 1 (2.6) |
Not Assessed | 14 (36.8) |
Abbreviation: RECIST = Response Evaluation Criteria in Solid Tumors.